

# Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

**CombiGene AB (publ) (the "Company") held an extraordinary general meeting ("EGM") on 10 December 2024 via digital connection. Below is a summary of the decisions passed at the EGM.**

## **Amendment of the Articles of Association**

The EGM resolved, in accordance with the shareholder Strategic Partner A/S's proposal, to amend the Articles of Association. The amendment was made in order to expand the scope of the business objectives, whereby the Company shall also have the opportunity to enter into strategic collaborations with other companies in other industries.

## **Board of Directors**

The EGM resolved, in accordance with the shareholder Strategic Partner A/S's proposal, that the Board of Directors shall consist of three ordinary Board members and one deputy Board member. Luca Di Stefano and Jakob Bendtsen were elected, and Marcus Isaksson was re-elected, as ordinary Board members and Lars Thunberg was elected as new deputy Board member. Furthermore, Luca Di Stefano was elected as Chairman of the Board of Directors.

## **Contacts**

---

*CombiGene AB (publ)*

Peter Ekolind, CEO

Phone: +46 (0)8 35 73 55

[peter.ekolind@combigene.com](mailto:peter.ekolind@combigene.com)

[www.combigene.com](http://www.combigene.com)

CombiGene AB (publ), Skeppsbron 38, SE-111 30 Stockholm, Sweden

+46-8-357355 [info@combigene.com](mailto:info@combigene.com)

## About CombiGene

---

CombiGene's vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company's Certified Advisor is Västra Hamnen Corporate Finance AB.

Sign up [here](#) to subscribe to Ingeneious News, a newsletter from CombiGene that contains general news and information that is deemed not to have a significant impact on the share price. Ingeneious News is also available at [combigene.com](https://combigene.com).